LARGO, Fla., Oct. 4 /PRNewswire-FirstCall/ -- GeoPharma, Inc. (Nasdaq: GORX) (the "Company") GeoPharma, Inc. announced today that it is proud to be among a select group invited to present at the EdgeWater Research Fall 2007 Small/Micro Cap Conference on Thursday, October 11, 2007 at 9:25 AM (PDT).
"EdgeWater Research Partners, has a long and respected history of isolating quality small cap companies that perform well in the marketplace", stated GeoPharma CEO Mihir K. Taneja. "Attendance at the EdgeWater Research Conference is just the beginning of GeoPharma's renewed efforts to communicate its agenda to Wall Street"."We are extremely pleased that EdgeWater included us."
Commenting on the story, EdgeWater Publisher and Analyst David Lavigne said, "As a subscription based service, the continued success of my business depends on my ability to consistently identify micro cap stories that have the potential to outperform the broader equity markets over the next 12 to 24 months." "When selecting companies to present at my conferences, this premise remains as one of the most important criteria I search for in an invitee." "Accordingly, I look forward to introducing GeoPharma to my attending subscribers."
The specifics of the presentation are as follow:
WHO: Mihir K. Taneja, CEO GeoPharma, Inc
WHEN: Thursday, October 11,
2007 at 9:25 AM ( PT)
WHERE: Loews Ventana Canyon Resort
7000 North Resort Drive
Tucson, AZ 85750
EdgeWater Research Partners, LLC is an independent micro cap equities research company representing the research of David Lavigne. EdgeWater follows a number of undiscovered small and micro cap stocks through both individual research and its monthly publication, The EdgeWater Micro Monthly. EdgeWater's research is distributed to its subscriber base, and is also available on a piece by piece basis on the Company's website, http://www.edgewaterresearch.com.
About GeoPharma, Inc:
GeoPharma, Inc. is a rapidly growing pharmaceutical company specializing in the manufacturing and distribution of over-the-counter, nutritional, generic drug and functional food products. GeoPharma manufactures, packages and distributes private label dietary supplements, over-the-counter and generic drugs, as well as, health and beauty products for companies worldwide. This is accomplished by utilizing our four Florida-incorporated companies, Innovative Health Products, Inc., Libi Labs, Belcher Pharmaceuticals, Inc. and Breakthrough Engineered Nutrition, Inc. Innovative Health Products and Libi Labs specialize in the development and manufacturing of a broad range of nutritional supplements and cosmeceuticals. As a private-label contract manufacturer, we develop and manufacture for ourselves, and our customers, dietary supplements and health and beauty care products for distribution through various outlets. Belcher Pharmaceuticals, Inc is a state-of-the-art FDA-registered, drug development and manufacturing facility for generic and over-the-counter drugs. Our fourth Florida Corporation, Breakthrough Engineered Nutrition, Inc., develops markets and distributes its own branded dietary supplements. DEX-L10, DEX-C20, OxyFirm and Cortiloss are Breakthrough's current dietary supplement brands. Breakthrough's products are distributed nationwide and internationally in specialty, food, drug and mass outlets, including Target, Wal-Mart, GNC, Walgreens, CVS, Rite Aid, Duane Reade and many others. We also have an established network of brokers and distributors strategically located across the United States and Canada. GeoPharma's growth strategy is to capitalize on its manufacturing expertise to develop high margin generic or novel drugs for niche markets with high barriers to entry. GeoPharma's competitive advantage lies in its ability to circumvent or overcome the challenges in these markets. For more about GeoPharma, Inc., go to our websites at http://www.geopharmainc.com, http://www.hoodiadexL10.com, and http://www.onlineihp.com
Safe Harbor Statement: This press release may contain statements, which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.
|SOURCE GeoPharma, Inc.|
Copyright©2007 PR Newswire.
All rights reserved